Twist Bioscience Corp (TWST) saw its stock price plummet by 5.20% in Tuesday's trading session, following a significant price target cut by JP Morgan analysts.
The sharp decline came after JP Morgan lowered its price target for Twist Bioscience from $40 to $33, maintaining an "Underweight" rating on the stock. This reduction in the price target suggests that the investment bank has become more pessimistic about the company's near-term prospects, which likely triggered a sell-off among investors.
While JP Morgan's downgrade seems to be the primary driver of the stock's decline, it's worth noting that Guggenheim maintained its price target for Twist Bioscience at $50 per share. This conflicting view from another analyst firm highlights the divergent opinions on the company's future performance. Investors appear to be giving more weight to JP Morgan's bearish stance in the short term, as reflected in the significant stock price drop.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。